Similar articles

• The hepatic fibrocystic diseases.

  Kerkar N, Norton K, Suchy FJ. Kerkar N, et al. Clin Liver Dis. 2006 Feb;10(1):55-71, v-vi. doi: 10.1016/j.cld.2005.10.003. Clin Liver Dis. 2006. PMID: 16376794 Review.
• Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.

  Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Van Keimpema L, et al. Liver Int. 2011 Jan;31(1):92-8. doi: 10.1111/j.1478-3231.2010.02247.x. Liver Int. 2011. PMID: 20408955
• Somatostatin analogues for treatment of polycystic liver disease.

  Gevers TJ, Drenth JP. Gevers TJ, et al. Curr Opin Gastroenterol. 2011 May;27(3):294-300. doi: 10.1097/MOG.0b013e328343433f. Curr Opin Gastroenterol. 2011. PMID: 21191289 Review.
• [Cystic liver].

  Reuteler C, Teuscher J. Reuteler C, et al. Schweiz Med Wochenschr. 1985 Oct 19;115(42):1450-3. Schweiz Med Wochenschr. 1985. PMID: 3906879 German.
• Somatostatin analogues reduce liver volume in polycystic liver disease.

  van Keimpema L, de Man RA, Drenth JP. van Keimpema L, et al. Gut. 2008 Sep;57(9):1338-9. doi: 10.1136/gut.2008.155721. Gut. 2008. PMID: 18719151 No abstract available.